BioCentury
ARTICLE | Clinical News

Celgosivir: Interim Phase II data

December 10, 2007 8:00 AM UTC

Interim 4-week data from a Phase II trial in 10 treatment-naïve patients showed that the median reduction in HCV RNA at 4 weeks was 3.5 log10 for celgosivir plus peginterferon alfa-2b and ribavirin vs...